Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 726 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Truck Driver Saves People From Bus Fire On Christmas Eve December 31, 2021 Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective January 17, 2023 Ivosidenib with Chemotherapy New Option for Some People with AML May 13, 2022 When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... January 23, 2023 Load more HOT NEWS Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications Study Suggests Statins May Help Keep Breast Cancer from Spreading to... Working to Close the Cancer Screening Gap Caused by COVID
